Cargando…

Antituberculosis Drug-Induced Fixed Drug Eruption: A Case Report

Fixed drug eruption (FDE) was caused by fixed-dose combination (FDC) of antituberculosis drugs in the form of tablet Forecox(®) (rifampicin [rifampin] 225 mg + isoniazid 150 mg + pyrazinamide 750 mg + ethambutol 400 mg) in a 40-year-old male patient with a history of drug allergy. The patient develo...

Descripción completa

Detalles Bibliográficos
Autores principales: Vaghela, Jitendra H., Nimbark, Vivek, Barvaliya, Manish, Mehta, Hita, Chavada, Bhavesh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5962523/
https://www.ncbi.nlm.nih.gov/pubmed/29785553
http://dx.doi.org/10.1007/s40800-018-0086-z
_version_ 1783324880702275584
author Vaghela, Jitendra H.
Nimbark, Vivek
Barvaliya, Manish
Mehta, Hita
Chavada, Bhavesh
author_facet Vaghela, Jitendra H.
Nimbark, Vivek
Barvaliya, Manish
Mehta, Hita
Chavada, Bhavesh
author_sort Vaghela, Jitendra H.
collection PubMed
description Fixed drug eruption (FDE) was caused by fixed-dose combination (FDC) of antituberculosis drugs in the form of tablet Forecox(®) (rifampicin [rifampin] 225 mg + isoniazid 150 mg + pyrazinamide 750 mg + ethambutol 400 mg) in a 40-year-old male patient with a history of drug allergy. The patient developed FDE after taking the third dose of tablet Forecox(®) for pulmonary tuberculosis. Tablet Forecox(®) was withdrawn and the patient recovered from the reaction after 15 days of treatment for FDE. As per World Health Organization–Uppsala Monitoring Centre (WHO-UMC) and Naranjo causality assessment criteria, the association between the reaction and tablet Forecox(®) was possible and probable, respectively. The reaction was moderately (Level 4b) severe according to the Modified Hartwig and Siegel scale. As there is an increased risk of allergic reaction in patients with a history of drug allergy, FDCs should not be used in order to avoid complexity in identifying the culprit drug.
format Online
Article
Text
id pubmed-5962523
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-59625232018-06-04 Antituberculosis Drug-Induced Fixed Drug Eruption: A Case Report Vaghela, Jitendra H. Nimbark, Vivek Barvaliya, Manish Mehta, Hita Chavada, Bhavesh Drug Saf Case Rep Case Report Fixed drug eruption (FDE) was caused by fixed-dose combination (FDC) of antituberculosis drugs in the form of tablet Forecox(®) (rifampicin [rifampin] 225 mg + isoniazid 150 mg + pyrazinamide 750 mg + ethambutol 400 mg) in a 40-year-old male patient with a history of drug allergy. The patient developed FDE after taking the third dose of tablet Forecox(®) for pulmonary tuberculosis. Tablet Forecox(®) was withdrawn and the patient recovered from the reaction after 15 days of treatment for FDE. As per World Health Organization–Uppsala Monitoring Centre (WHO-UMC) and Naranjo causality assessment criteria, the association between the reaction and tablet Forecox(®) was possible and probable, respectively. The reaction was moderately (Level 4b) severe according to the Modified Hartwig and Siegel scale. As there is an increased risk of allergic reaction in patients with a history of drug allergy, FDCs should not be used in order to avoid complexity in identifying the culprit drug. Springer International Publishing 2018-05-21 /pmc/articles/PMC5962523/ /pubmed/29785553 http://dx.doi.org/10.1007/s40800-018-0086-z Text en © The Author(s) 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Case Report
Vaghela, Jitendra H.
Nimbark, Vivek
Barvaliya, Manish
Mehta, Hita
Chavada, Bhavesh
Antituberculosis Drug-Induced Fixed Drug Eruption: A Case Report
title Antituberculosis Drug-Induced Fixed Drug Eruption: A Case Report
title_full Antituberculosis Drug-Induced Fixed Drug Eruption: A Case Report
title_fullStr Antituberculosis Drug-Induced Fixed Drug Eruption: A Case Report
title_full_unstemmed Antituberculosis Drug-Induced Fixed Drug Eruption: A Case Report
title_short Antituberculosis Drug-Induced Fixed Drug Eruption: A Case Report
title_sort antituberculosis drug-induced fixed drug eruption: a case report
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5962523/
https://www.ncbi.nlm.nih.gov/pubmed/29785553
http://dx.doi.org/10.1007/s40800-018-0086-z
work_keys_str_mv AT vaghelajitendrah antituberculosisdruginducedfixeddrugeruptionacasereport
AT nimbarkvivek antituberculosisdruginducedfixeddrugeruptionacasereport
AT barvaliyamanish antituberculosisdruginducedfixeddrugeruptionacasereport
AT mehtahita antituberculosisdruginducedfixeddrugeruptionacasereport
AT chavadabhavesh antituberculosisdruginducedfixeddrugeruptionacasereport